Background: Limitations of Existing LNP-Induced Systemic Inflammatory Responses and Bottlenecks in Exogenous Toll-like Receptor Activation Data for Infectious Disease Vaccine R&D

The first-generation mRNA-LNP vaccine architectures, Comirnaty and Spikevax, successfully induced rapid immune responses but faced safety bottlenecks due to systemic inflammatory responses and off-target immune overactivation. Specifically, the endogenous adjuvant activity induced by ionizable lipids leads to cellular disruption-related structural collapse noise and individual-specific heterogeneous Toll-like receptor (TLR3, TLR7, TLR8) sensing fluxes, making it difficult to predict in vivo translational efficiency and consistent delivery to target immune cells. Existing simple, linear, and static analysis standard guidelines cannot track or control the dynamic changes within the microenvironment necessary to maintain in vivo effective prophylactic concentrations. This generates false-positive data noise due to interspecies differences and immune tolerance feedback fluxes, ultimately creating a critical data barrier that leads to unpredictable deviations during the transition from preclinical efficacy to actual clinical trials. Therefore, it is urgently necessary to introduce a high-resolution omics integration architecture that can multidimensionally map immunogenic regulatory factors and LNP physicochemical composition and computationally control them in silico.

Discovery: Implementation of N1-Methylpseudouridine Modification Algorithm and Demonstration of Single-Cell Transcriptome Scale Cytokine Expression Tensor Synchronization

This study (doi:10.1038/s41586-026-10599-0) demonstrates a platform that fine-tunes immune responses by linking an mRNA chemical modification technology, the N1-methylpseudouridine (N1-methylpseudouridine) substitution rate control algorithm, with the lipid composition ratio tensor of LNP. The researchers operated a differential equation model that adjusts the LNP surface charge and the free energy of hydrophobic core binding to preemptively calculate the intracellular antigen translation rate constant. They profiled the transcriptome network of dendritic cells and macrophages within the lymph node microenvironment at the single-cell level, computationally removing batch effects, and demonstrated immunogenicity prediction capabilities that surpass existing static vaccine models. In particular, computational optimization of the mRNA 5' UTR and 3' UTR sequence structures maximized ribosomal loading efficiency, and the topological variation curve of downstream transcriptome networks that precisely control the expression threshold of systemic inflammatory cytokines such as IFN-alpha and IL-6 was elucidated, demonstrating molecular biological integrity.

Modeling of Follicular Helper T Cell (Tfh) Pathway Modulation and Establishment of a Reversible Germinal Center Homeostasis Precision Layered Model

The study modeled the spatiotemporal signaling hubs of follicular helper T cells (Tfh) and germinal center (GC) B cell differentiation pathways, which are critical for vaccine persistence and neutralizing antibody formation. Based on omics matrix information, patient-specific and molecular phenotype-specific precision layering was performed to refine the immune-inducing expression profile. By up- and down-regulating the rate-limiting step constants in the binding kinetics between the major histocompatibility complex (MHC) class II of antigen-presenting cell membranes and T cell receptors (TCRs), a control backbone was established that can reversibly modulate homeostasis even under inflammatory stimuli. This successfully established a mechanism for maintaining microenvironmental homeostasis within lymph nodes that induces antibody affinity maturation while minimizing in vivo adverse effects by selectively stimulating the BCL6 transcription factor and IL-21 cytokine secretion loop that govern Tfh cell differentiation.

Prospects: Establishment of a Programmable Computational Immunology Standard and Launch of a Next-Generation IND Digital Governance

This technology completely resets R&D governance from the existing post-hoc analysis system to a programmable computational immunology infrastructure based on AI-driven multidimensional tensor. In the global mRNA vaccine and new drug development market, which is estimated at $68 billion in 2026, the high-throughput screening genetic gradient correction coefficient linkage function of this platform provides a computational moat that eliminates batch-to-batch variations. When multinational pharmaceutical companies develop next-generation cancer vaccines and treatments for intractable infectious diseases, the virtual docking prediction model that meets this digital companion diagnostic (CDx) standard will drastically shorten the IND approval evaluation framework timeline. As a result, it is expected to be established as a global governance standard master asset that organically links to cGMP commercial production approval, maximizing clinical success.